Small-molecule activation of lysosomal TRP channels ameliorates Duchenne muscular dystrophy in mouse models

Science Advances
Lu YuHaoxing Xu

Abstract

Duchenne muscular dystrophy (DMD) is a devastating disease caused by mutations in dystrophin that compromise sarcolemma integrity. Currently, there is no treatment for DMD. Mutations in transient receptor potential mucolipin 1 (ML1), a lysosomal Ca2+ channel required for lysosomal exocytosis, produce a DMD-like phenotype. Here, we show that transgenic overexpression or pharmacological activation of ML1 in vivo facilitates sarcolemma repair and alleviates the dystrophic phenotypes in both skeletal and cardiac muscles of mdx mice (a mouse model of DMD). Hallmark dystrophic features of DMD, including myofiber necrosis, central nucleation, fibrosis, elevated serum creatine kinase levels, reduced muscle force, impaired motor ability, and dilated cardiomyopathies, were all ameliorated by increasing ML1 activity. ML1-dependent activation of transcription factor EB (TFEB) corrects lysosomal insufficiency to diminish muscle damage. Hence, targeting lysosomal Ca2+ channels may represent a promising approach to treat DMD and related muscle diseases.

References

Jul 1, 1980·Muscle & Nerve·D DanilowiczD Schively
Oct 23, 1997·The Journal of Cell Biology·V StraubK P Campbell
May 9, 2003·Nature·Dimple BansalKevin P Campbell
Sep 1, 2004·Neuromuscular Disorders : NMD·John G QuinlanLinda S Levin
Jan 8, 2005·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·James G Tidball
Sep 15, 2006·Nature Reviews. Molecular Cell Biology·Kay E Davies, Kristen J Nowak
Mar 5, 2008·The Journal of Cell Biology·Vincent IdoneNorma W Andrews
Dec 2, 2008·Nature Cell Biology·Chuanxi CaiJianjie Ma
Jan 6, 2009·Nature Cell Biology·Paul McNeil
Feb 18, 2010·Future Medicinal Chemistry·Eric MillsHaoxing Xu
Oct 20, 2010·Proceedings of the National Academy of Sciences of the United States of America·Candace M AdamoJoseph A Beavo
Sep 6, 2011·Developmental Cell·Diego L MedinaAndrea Ballabio
Sep 9, 2011·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Lisa M LarkinSusan V Brooks
Jan 25, 2013·Cellular and Molecular Life Sciences : CMLS·Stephanie DuguezTerence Partridge
Mar 8, 2013·Lancet·Eugenio Mercuri, Francesco Muntoni
Apr 23, 2013·EMBO Molecular Medicine·Carmine SpampanatoNina Raben
May 15, 2013·The Journal of Cell Biology·Fedik Rahimov, Louis M Kunkel
Feb 11, 2015·Annual Review of Physiology·Haoxing Xu, Dejian Ren
Feb 28, 2015·Nature Cell Biology·Diego L MedinaAndrea Ballabio
Mar 4, 2015·Proceedings of the National Academy of Sciences of the United States of America·Wuyang WangHaoxing Xu
Nov 1, 2015·Seminars in Cell & Developmental Biology·Xiping ChengHaoxing Xu
Jul 1, 2016·Nature Communications·Xiaoli ZhangHaoxing Xu
Sep 1, 2016·Journal of Cell Science·Bethan S KilpatrickSandip Patel
Apr 11, 2017·Molecular Therapy : the Journal of the American Society of Gene Therapy·Apurva SarathyDean J Burkin
Dec 1, 2017·Science Translational Medicine·Leonela AmoasiiEric N Olson
Nov 15, 2018·Trends in Biochemical Sciences·Ping LiHaoxing Xu

❮ Previous
Next ❯

Citations

Aug 9, 2020·Circulation Research·Abhinav Diwan, Roberta A Gottlieb
Jan 18, 2021·Neuromuscular Disorders : NMD·Alberto A ZambonUNKNOWN Genomics England Research Consortium
Apr 27, 2021·Frontiers in Physiology·Satvik MareeduGopal J Babu
Sep 28, 2021·Human Molecular Genetics·Sarah J SmithJames J Dowling

❮ Previous
Next ❯

Methods Mentioned

BETA
transgenic
PCR
genotyping
nuclear translocation
Assay
irradiate
transfection

Software Mentioned

Maxchelator
MetaMorph Advanced Imaging
ImageJ
Origin
pClamp

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.